I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics" Ross

Self-docking and cross-docking simulations of G protein-coupled receptor-ligand complexes: Impact of of 11 Class A GPCR crystallized in multiple activation states (giving rise to 37 self-docking and 68 cross Our results show that one specific subset of cross-docking simulations gave results of similar quality RMSD values for top-scored poses were 1.2 Å and 2.0 Å for self-docking and StateMatch/FunctionMatch cross-docking

GPCR Priming: The Hidden Synergy in Cellular Signalling Alberto Gonzalez-Hernandez, Hermany Munguba, Joshua

Joshua Gross were enthusiastic about the idea and jumped on board. Dylan Eiger , and Joshua Gross. We are very excited about this event.

aligned with strategy, not spreadsheets Set up clear deliverables across internal and CRO teams Keep cross-functional Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution

. << Back to podcast list Strategic Partner(s) Ross Cheloha: Nanobody-GPCR Conjugates and the Engineering Ross Cheloha approaches these questions from a chemical biology perspective - using synthetic peptide About the Guest Ross Cheloha is a tenure-track investigator at the National Institute of Diabetes and Ross Cheloha is an Investigator at the National Institutes of Health in the Laboratory of Bioorganic Ross Cheloha on the web NIDDK Cheloha Lab Google Scholar LinkedIn Twitter ResearchGate Dr.